Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248305 | 0.78 | PDGFRB (0.40) | PDGFRBPDGFRAPTGDR2HTR2APDE4B | |
| SCHEMBL16248037 | 0.74 | HTR2A (0.39) | PDGFRBPDGFRAPTGDR2HTR2APDE4B | |
| SCHEMBL17450270 | 0.72 | HTR2A (0.37) | PDGFRBPDGFRAPTGDR2HTR2APDE4B | |
| SCHEMBL19953401 | 0.71 | CNR2 (0.36) | PDGFRBPDGFRAPTGDR2HTR2APDE4B | |
| SCHEMBL28305102 | 0.71 | PTGDR2 (0.48) | PTGDR2ALDH1A1HPGDRAB9AMAPT | |
| SCHEMBL2094053 | 0.70 | PDE4A (0.54) | PDGFRBPDGFRAPTGDR2HTR2APDE4B | |
| SCHEMBL27836626 | 0.68 | ALDH1A1 (0.46) | PDGFRBPDGFRAHTR2APDE4BPDE4A | |
| SCHEMBL24454645 | 0.66 | LMNA (0.33) | ALDH1A1HPGDLMNATP53KMT2A | |
| SCHEMBL9325871 | 0.65 | PDE4A (0.59) | PDGFRBPDGFRAPDE4BPDE4APDE4C | |
| SCHEMBL21104922 | 0.64 | ACHE (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| CN-115557907-B | 2,4, 5-Trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| CN-115215886-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-01 | — | — | US | disclosed |
| CN-115557907-A | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| WO-2017157992-A1 | ANNULATED PYRAZOLES AS BUB1 KINASE INHIBITORS FOR TREATING PROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017157991-A1 | 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| EP-3194381-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194379-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194380-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194378-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016041925-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042084-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042080-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042081-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | PDGFRB 2087/4885PDGFRA 2422/4885PTGDR2 406/4885 |
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDGFRB 320/4885PDGFRA 563/4885PTGDR2 2884/4885 |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | PDGFRB 2087/4885PDGFRA 2422/4885PTGDR2 406/4885 |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | PDGFRB 1780/4885PDGFRA 1253/4885PTGDR2 980/4885 |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DHPS, DPYD | PDGFRB 2087/4885PDGFRA 2422/4885PTGDR2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.